))
ANCA Vasculitis and the Complement System, Part 2: On to the Humans
Manage episode 407440403 series 3560282
Content provided by Healio, Adam J. Brown, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio, Adam J. Brown, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The final episode summarizes the human data on complement in ANCA vasculitis, with a quick discussion of the trials of C5a receptor antagonism.
Brought to you by Actemra.
- Intro :10
- Welcome :21
- Recap of previous episodes :22
- In this episode 2:12
- Let’s start with neutrophil data 5:24
- Studies in humans 11:54
- A summary of the data so far 21:20
- What does all this amount to? 25:41
- Trials of avacopan 28:25
- Side effect profile 36:25
- Thanks for listening 37:06
Disclosures: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Augusto JF, et al. PLoS One. 2016;https://doi.org/10.1371/journal.pone.0158871.
Bekker P, et al. PLoS One. 2016;https://doi.org/10.1371/journal.pone.0164646.
Chen SF, et al. Arthritis Res Ther. 2015;https://doi.org/10.1186/s13075-015-0656-8.
Falk RJ, et al. Proc Natl Acad Sci USA. 1990;87:4115-4119.
Gou SJ, et al. Clin J Am Soc Nephrol. 2013;8:1884-1891.
Gou SJ, et al. Kidney Int. 2013;83:129-137.
Jayne DRW, et al. J Am Soc Nephrol. 2017;28:2756-2767.
Jayne DRW, et al. N Engl J Med. 2021;384:599-609.
Merkel PA, et al. ACR Open Rheumatol. 2020;2:662-671.
83 episodes
Share
